Form 4: Arcutis Biotherapeutics Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Masaru Matsuda, Senior Vice President, General Counsel, and Corporate Secretary of Arcutis Biotherapeutics, sold shares to cover tax obligations related to vesting Restricted Stock Units.
Summary
- Masaru Matsuda, an executive at Arcutis Biotherapeutics, sold 8,338 shares of common stock on February 3, 2025, at a weighted average price of $12.7 per share.
- The sale was to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs) granted on January 12, 2024.
- 25% of the RSUs vest annually beginning on February 1, 2025, subject to continued service.
- Following the transaction, Matsuda beneficially owns 178,692 shares of Arcutis Biotherapeutics.
- The reported holdings also reflect adjustments for shares acquired under the Employee Stock Purchase Plan on May 31, 2024 (4,000 shares) and November 30, 2024 (1,657 shares), which were previously misreported.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of an insider transaction for tax purposes, with a minor correction of a previous reporting error.
Positives
- The filing corrects a previous error in reporting shares acquired through the Employee Stock Purchase Plan, providing a more accurate view of the executive's holdings.
Future Outlook
The document does not contain any specific forward-looking statements or guidance.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the trading activities of company executives. It's common for executives to sell shares to cover tax obligations related to equity compensation.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading activities.
- Similar filings are made by executives at comparable companies like Dermavant Sciences and Incyte Corporation when they execute stock transactions.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding executive stock transactions.
- The correction of the previous reporting error ensures accurate information for investors.
Key Dates
| Date | Description |
|---|---|
| January 12, 2024 | Date of RSU grant. |
| May 31, 2024 | Acquisition of 4,000 shares under the Employee Stock Purchase Plan. |
| November 30, 2024 | Acquisition of 1,657 shares under the Employee Stock Purchase Plan. |
| February 1, 2025 | Vesting Commencement Date for RSUs. |
| February 3, 2025 | Date of stock sale. |
| February 4, 2025 | Date of Form 4 filing. |
Keywords
Arcutis Biotherapeutics, ARQT, Masaru Matsuda, Form 4, insider trading, stock sale, RSU, tax obligations, Employee Stock Purchase Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.